Alto Neuroscience Net Income Over Time
| ANRO Stock | 16.71 0.06 0.36% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alto Neuroscience Performance and Alto Neuroscience Correlation. Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value - what Alto Neuroscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Alto Neuroscience and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | (207.7 M) | 719 M | 433.7 M | 276.5 M | (134.9 M) | 1.4 B | 414.5 M | 1.7 B | 855.4 M | (3.4 B) | 1.5 B | 1.7 B | 1.7 B | 1.5 B | 1.6 B | 1.8 B | 1.9 B |
| REGN | (3.3 M) | (221.8 M) | 750.3 M | 424.4 M | 348.1 M | 636.1 M | 895.5 M | 1.2 B | 2.4 B | 2.1 B | 3.5 B | 8.1 B | 4.3 B | 4 B | 4.4 B | 4.5 B | 4.7 B |
| IDXX | 3.2 M | 161.8 M | 178.3 M | 187.8 M | 181.9 M | 192.1 M | 222 M | 263.1 M | 377 M | 427.7 M | 581.8 M | 744.8 M | 679.1 M | 845 M | 887.9 M | 1.1 B | 1.1 B |
| HLN | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 1.1 B | 1.4 B | 1.1 B | 1 B | 1.4 B | 1.7 B | 1.2 B |
| CI | (854.6 M) | 1.3 B | 1.6 B | 1.5 B | 2.1 B | 2.1 B | 1.9 B | 2.2 B | 2.6 B | 5.1 B | 8.5 B | 5.4 B | 6.7 B | 5.2 B | 3.4 B | 6 B | 6.3 B |
| ELV | 172.4 M | 2.6 B | 2.7 B | 2.7 B | 2.6 B | 2.6 B | 2.5 B | 3.8 B | 3.8 B | 4.8 B | 4.6 B | 6.1 B | 5.9 B | 6 B | 6 B | 5.7 B | 3.3 B |
| BDX | 88 M | 1.2 B | 1.3 B | 1.2 B | 695 M | 976 M | 1.1 B | 311 M | 1.2 B | 874 M | 2.1 B | 1.8 B | 1.5 B | 1.7 B | 1.7 B | 1.9 B | 2 B |
| ARGX | (4.5 M) | (4.5 M) | (12.8 M) | (8.5 M) | (12.5 M) | (16.7 M) | (22.5 M) | (33.7 M) | (76.2 M) | (181.2 M) | (608.5 M) | (407.6 M) | (709.6 M) | (295.1 M) | 833 M | 749.7 M | 787.2 M |
Alto Neuroscience and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Alto Neuroscience financial statement analysis. It represents the amount of money remaining after all of Alto Neuroscience operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Alto Neuroscience | ANRO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 650 Castro Street, |
| Exchange | New York Stock Exchange |
null 16.71
Check out Alto Neuroscience Performance and Alto Neuroscience Correlation. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Alto Neuroscience technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.